- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.10. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 13.10. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 02.10. | NeuroSense Provides Update on Nasdaq Listing Compliance | 333 | PR Newswire | Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance... ► Artikel lesen | |
| 25.09. | NeuroSense Therapeutics GAAP EPS of -$2.10 beats by $1.83 | 3 | Seeking Alpha | ||
| 25.09. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 15.09. | XFRA H1Z: WIEDERAUFNAHME/RESUMPTION | 242 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 14.09. | XFRA H1Z: AUSSETZUNG/SUSPENSION | 341 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNEUROSENSE THERAPEUTICS... ► Artikel lesen | |
| 14.09. | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.09.2026 | 369 | Xetra Newsboard | Das Instrument USZ0 AU0000284366 BPH GLOBAL LTD. EQUITY wird cum Kapitalmassnahme gehandelt am 14.09.2026 und ex Kapitalmassnahme am 15.09.2026 The instrument USZ0 AU0000284366 BPH GLOBAL LTD. EQUITY... ► Artikel lesen | |
| NEUROSENSE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.09. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 13.08. | NeuroSense Issues CEO Letter to Shareholders | 387 | PR Newswire | CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused... ► Artikel lesen | |
| 06.08. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.07. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 29.06. | NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS | 278 | PR Newswire | First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALS
TDP-43 pathology is... ► Artikel lesen | |
| 25.06. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 25.06. | NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease | 366 | PR Newswire | PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with... ► Artikel lesen | |
| 18.06. | Halberd Corp.: Halberd Corporation Ships Latest NeuroSense AI Version, Advancing Voice-Based Behavioral Monitoring | 3 | GlobeNewswire (USA) | ||
| 08.06. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 03.04. | NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements | 374 | PR Newswire | Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq
Nasdaq has provided the Company until September 29, 2026... ► Artikel lesen | |
| 31.03. | NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update | 677 | PR Newswire | 2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS
Statistically significant survival benefit demonstrated... ► Artikel lesen | |
| 16.03. | NeuroSense: JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity | 486 | PR Newswire | The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARDIOL THERAPEUTICS | 0,844 | -4,63 % | Cardiol Therapeutics drops after launching a $75M ATM offering | ||
| CELLECTAR BIOSCIENCES | 1,270 | +1,60 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,144 | -0,69 % | Redwood AI Corp.: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen | |
| CEL-SCI | 1,180 | +3,51 % | CEL-SCI Corporation: CEL-SCI Presents New Phase 3 Multikine Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival | Target Population Selection: Biomarker profile applied prior to treatment of locally advanced disease with no lymph node involvement (N0) and low/zero tumor PD-L1 expression (TPS 10%) or zero... ► Artikel lesen | |
| MOLECULIN BIOTECH | 7,579 | 0,00 % | Moleculin Biotech, Inc.: Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting | ||
| PDS BIOTECHNOLOGY | 1,125 | +2,27 % | PDS Biotechnology Corporation: PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors | Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation... ► Artikel lesen | |
| LISATA THERAPEUTICS | 0,835 | +0,60 % | Lisata Therapeutics, Inc.: Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly | Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks... ► Artikel lesen | |
| GEOVAX LABS | 0,158 | +0,06 % | GeoVax Labs, Inc. - 8-K, Current Report | ||
| COCRYSTAL | 0,865 | 0,00 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors | BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| GOSSAMER BIO | 8,666 | -2,23 % | XFRA 4GB0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| DECOY THERAPEUTICS | 1,130 | 0,00 % | Decoy Therapeutics plant Einreichung für Coronavirus-Wirkstoff im zweiten Halbjahr 2027 | ||
| JASPER THERAPEUTICS | 16,750 | -0,65 % | Jasper Therapeutics to execute 1-for-30 reverse stock split | ||
| CHEMOMAB THERAPEUTICS | 1,290 | -2,27 % | Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer | ||
| VISTAGEN THERAPEUTICS | 0,165 | +0,73 % | Vistagen Therapeutics, Inc.: Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety Disorder | Exploratory research results presented at Psych Congress 2026 in New Orleans Full poster presentation can be found on "Publications" section of Company's website SOUTH SAN FRANCISCO, Calif., Sept.... ► Artikel lesen | |
| IN8BIO | 0,735 | -9,82 % | IN8bio, Inc: IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
Das Unternehmen NEUROSENSE THERAPEUTICS LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,240 Euro und damit +3,33 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUROSENSE THERAPEUTICS LTD finden Sie auf Wallstreet Online.